BNTX BioNTech SE - ADR

36.7
-2.18  -6%
Previous Close 38.88
Open 37.21
Price To Book 17.9
Market Cap 8,322,816,605
Shares 226,779,744
Volume 192,946
Short Ratio
Av. Daily Volume 216,918
Stock charts supplied by TradingView

NewsSee all news

  1. BioNTech to acquire Neon to strengthen global leadership position in T cell therapies

    Further expands BioNTech's growing CAR-T and TCR therapy pipeline through addition of neoantigen specific cell therapies, including a T cell therapy targeting shared RAS oncogenesAccelerates BioNTech's global expansion

  2. BioNTech Appoints Ryan Richardson as Chief Strategy Officer to Support its Continued Global Expansion

    MAINZ, Germany, Jan. 13, 2020 (GLOBE NEWSWIRE) -- BioNTech SE (NASDAQ:BNTX, "BioNTech" or "the Company")), announced today that the Supervisory Board has appointed Ryan Richardson to the Management Board as Chief

  3. BioNTech Announces Publication of Preclinical Data for First-in-Kind CAR-T Cell Therapy Approach Targeting Solid Tumors in Science

    Publication of preclinical proof-of-concept data for BNT211 reports Claudin 6 (CLDN6) as a novel target for CAR-T cell therapy of solid tumors and introduces CARVac, a first-in-kind RNA vaccine approach promoting the

  4. BioNTech to Present at the 38th Annual J.P. Morgan Healthcare Conference

    MAINZ, Germany, Dec. 18, 2019 (GLOBE NEWSWIRE) -- BioNTech SE (NASDAQ:BNTX) today announced that CEO and Co-founder Ugur Sahin, MD, will present at the 38th Annual J.P. Morgan Healthcare Conference on Wednesday,

  5. European Investment Bank provides funding of €50 million to BioNTech as part of the Investment Plan for Europe

    Funds will support BioNTech's research and development of cancer treatmentsFinancing by EU bank is provided under Investment Plan for Europe, or Juncker Plan LUXEMBOURG and MAINZ, Germany, Dec. 17, 2019 (GLOBE

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 1 data update 2H 2020.
BNT131
Solid tumors
Phase 1 trial to resume 4Q 2019.
BNT321
Pancreatic cancer
Phase 1 data update 1H 2021.
BNT312
Solid tumors
Phase 1 data update 1H 2021.
BNT311
Solid tumors
Phase 1 data update 2020.
BNT122
Solid tumors
Phase 2 top-line data due 2H 2020.
BNT122
Melanoma
Phase 1 data update due 1H 2020.
BNT114
Triple negative breast cancer
Phase 2 trial to commence 2H 2020.
BNT113
Head and Neck Cancer / HPV
Phase 1 data due 1H 2020.
BNT111
Melanoma
Phase 1/2 trial to commence 1H 2020 with data due 2022.
BNT211
Solid tumors
Phase 1/2 data due 2022.
BNT112
Prostate cancer
Phase 1 trial to commence 1H 2020 with data due 2022.
BNT151
Solid tumors

Latest News

  1. BioNTech to acquire Neon to strengthen global leadership position in T cell therapies

    Further expands BioNTech's growing CAR-T and TCR therapy pipeline through addition of neoantigen specific cell therapies, including a T cell therapy targeting shared RAS oncogenesAccelerates BioNTech's global expansion

  2. BioNTech Appoints Ryan Richardson as Chief Strategy Officer to Support its Continued Global Expansion

    MAINZ, Germany, Jan. 13, 2020 (GLOBE NEWSWIRE) -- BioNTech SE (NASDAQ:BNTX, "BioNTech" or "the Company")), announced today that the Supervisory Board has appointed Ryan Richardson to the Management Board as Chief

  3. BioNTech Announces Publication of Preclinical Data for First-in-Kind CAR-T Cell Therapy Approach Targeting Solid Tumors in Science

    Publication of preclinical proof-of-concept data for BNT211 reports Claudin 6 (CLDN6) as a novel target for CAR-T cell therapy of solid tumors and introduces CARVac, a first-in-kind RNA vaccine approach promoting the

  4. BioNTech to Present at the 38th Annual J.P. Morgan Healthcare Conference

    MAINZ, Germany, Dec. 18, 2019 (GLOBE NEWSWIRE) -- BioNTech SE (NASDAQ:BNTX) today announced that CEO and Co-founder Ugur Sahin, MD, will present at the 38th Annual J.P. Morgan Healthcare Conference on Wednesday,

  5. European Investment Bank provides funding of €50 million to BioNTech as part of the Investment Plan for Europe

    Funds will support BioNTech's research and development of cancer treatmentsFinancing by EU bank is provided under Investment Plan for Europe, or Juncker Plan LUXEMBOURG and MAINZ, Germany, Dec. 17, 2019 (GLOBE

  6. BioNTech SE Provides Update on Corporate Progress and Third Quarter 2019 Financial Results

    Successfully transferred IND for BNT321 to BioNTech. All necessary safety and other reports and an updated protocol filed with the FDA. Phase 1/2 trial of BNT321 expected to be re-initiated in the fourth quarter of

  7. BioNTech to Report Third Quarter 2019 Financial Results and Operational Progress on November 14, 2019

    MAINZ, Germany, Nov. 07, 2019 (GLOBE NEWSWIRE) -- BioNTech SE (NASDAQ:BNTX, "BioNTech" or "the Company")), a clinical-stage biotechnology company focused on patient-specific immunotherapies for the treatment of cancer